Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.70 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16317484 | 1.00 | VDR (0.76) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL4156343 | 0.89 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14005325 | 0.87 | VDR (0.65) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14030848 | 0.87 | VDR (0.73) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL13392197 | 0.87 | VDR (0.73) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL14005440 | 0.87 | VDR (0.73) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL14005544 | 0.87 | VDR (0.73) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL19988205 | 0.87 | VDR (1.00) | VDRHDAC6HDAC3CYP24A1 | |
| SCHEMBL3056435 | 0.87 | VDR (1.00) | VDRHDAC6HDAC3CYP24A1 | |
| SCHEMBL12047912 | 0.87 | VDR (1.00) | VDRHDAC6HDAC3CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | VDR 1/4885HDAC6 896/4885HDAC3 943/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC6 1458/4885HDAC3 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.